Question to the Department of Health and Social Care:

To ask the Secretary of State for Health, what treatments are approved for use by the NHS for patients diagnosed with generalised and partial lipodystrophy.

Beyond standard management of diabetes and cardiovascular risk, no specific treatments are approved. However, Leptin is supplied from the Cambridge Severe Insulin Resistance service on a named patient basis, funded through a research trial.

NHS England is developing a policy to consider the use of metreleptin for patients with lipodystrophy during 2017/18. The National Institute for Health and Care Excellence (NICE) is currently developing guidance on the use of metreleptin for the treatment of lipodystrophy through its highly specialised technology evaluation programme. NICE currently expects to issue final guidance in September 2018.